CSGP:NASDAQCoStar Group, Inc. Analysis
Data as of 2026-03-10 - not real-time
$46.19
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
CoStar Group (CSGP) is trading around $46, which sits below its 20‑day SMA of $47.26 and well under the 50‑day SMA of $56.16, indicating short‑term weakness. The RSI of 38 points to bearish momentum, while the MACD line remains negative despite a bullish histogram, confirming a bearish technical outlook. Volume is on a decreasing trend and 30‑day volatility is extremely high at over 70%, adding to short‑term uncertainty. Fundamental metrics are stark: a trailing PE of 2,309 dwarfs the industry average of 33, and the discounted cash‑flow fair value of roughly $14 suggests the stock is severely overvalued. The market’s sentiment index shows “Extreme Greed,” yet the underlying valuation gap creates a substantial risk of correction.
Recent material news includes a Q4 earnings beat with 27% revenue growth, strong insider buying by the CEO and other executives, and upgrades from BTIG and Jefferies to “Buy,” which provide a modest bullish catalyst. Conversely, Jim Cramer’s AI‑related concerns and the stock’s 27% drop in February highlight lingering market skepticism. Analyst consensus remains “Buy” with a median price target near $65, implying a potential upside but still far above intrinsic estimates. The combination of bearish technical signals, high volatility, and a massive valuation premium suggests caution, especially for short‑term traders.
Recent material news includes a Q4 earnings beat with 27% revenue growth, strong insider buying by the CEO and other executives, and upgrades from BTIG and Jefferies to “Buy,” which provide a modest bullish catalyst. Conversely, Jim Cramer’s AI‑related concerns and the stock’s 27% drop in February highlight lingering market skepticism. Analyst consensus remains “Buy” with a median price target near $65, implying a potential upside but still far above intrinsic estimates. The combination of bearish technical signals, high volatility, and a massive valuation premium suggests caution, especially for short‑term traders.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 7/10
Key Factors
- Price below 20‑day and 50‑day SMAs
- Bearish RSI and MACD momentum
- High volatility and decreasing volume
Medium Term
1–3 yearsNeutral
Model confidence: 6/10
Key Factors
- Strong revenue growth and earnings beat
- Analyst upgrades and insider buying support
- Persistent overvaluation relative to DCF
Long Term
> 3 yearsCautious
Model confidence: 8/10
Key Factors
- Massive PE disparity versus industry
- DCF fair value far below current price
- Sustained bearish technical trend and volatility
Key Metrics & Analysis
Financial Health
Revenue Growth26.90%
Profit Margin0.22%
P/E Ratio2309.5
ROE0.09%
ROA-0.34%
Debt/Equity13.67
P/B Ratio2.3
Op. Cash Flow$430.0M
Free Cash Flow$143.8M
Industry P/E33.1
Technical Analysis
TrendBearish
RSI38.1
Support$43.16
Resistance$52.35
MA 20$47.26
MA 50$56.16
MA 200$73.83
MACDBullish
VolumeDecreasing
Fear & Greed Index78.66
Valuation
Fair Value$14.05
Target Price$65.42
Upside/Downside41.63%
GradeOvervalued
TypeGrowth
Risk Assessment
Beta0.89
Volatility70.11%
Sector RiskMedium
Reg. RiskLow
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.